Molecular imaging in prostate cancer

Molecular Imaging in Oncology

Volumn , Issue , 2008, Pages 623-643

  Cho, Steve Y ^a   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85062750164     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (166)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007; 57(1):43-66.
2. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243(1):28-53.
3. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007; 82(2):243-249.
4. Kattan MW, Stapleton AM, Wheeler TM, et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79(3): 528-537.
5. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreat-ment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18(19):3352-3359.
6. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176(13): 1853-1858.
7. Saitoh H, Yoshida K, Uchijima Y, et al. Two different lymph node metastatic patterns of a prostatic cancer. Cancer 1990; 65(8):1843-1846.
8. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003; 30(4):677-686.
9. Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69(4):714-720.
10. Shinohara K, Wheeler TM, Scardino PT. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 1989; 142(1):76-82.
11. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987; 162(2):331-336.
12. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213(2):473-180.
13. Tuzel E, Sevinc M, Obuz F, et al. Is magnetic resonance imaging necessary in the staging of prostate cancer? Urol Int 1998; 61(4):227-231.
14. Lawrentschuk N, Davis ID, Bolton DM, et al. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int J Urol 2007; 14(2): 89-95.
15. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145(2):313-318.
16. Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269(1):57-60.
17. Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 1999; 35(3): 223-227.
18. Yap BK, Choo R, Deboer G, et al. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int 2003; 91(7):613-617.
19. Turlakow A, Larson SM, Coakley F, et al. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 2001; 45(3):235-244.
20. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36(1):31-35.
21. Nunez R, Macapinlac HA, Yeung HW, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43(1):46-55.
22. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199(3):751-756.
23. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4(1):99-104.
24. Chang CH, Wu HC, Tsai JJ, et al. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003; 70(4):311-315.
25. Schoder H, Herrmann K, Gonen M, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11(13):4761-1769.
26. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglu-cose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005; 11(9):3210-3216.
27. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6(suppl 10):S13-S18.
28. Wright GL Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48(2):326-334.
29. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3(1):81-85.
30. Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000; 43(2):150-157.
31. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7(5B):927-935.
32. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3(4):216-225.
33. Wynant GE, Murphy GP, Horoszewicz JS, et al. Immu-noscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5. 3 (CYT-356). Prostate 1991; 18(3):229-241.
34. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintig-raphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54(6):1058-1063.
35. Kahn D, Williams RD, Haseman MK, et al. Radioimmu-noscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998; 16(1):284-289.
36. Levesque PE, Nieh PT, Zinman LN, et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998; 51(6):978-984.
37. Deb N, Goris M, Trisler K, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996; 2(8):1289-1297.
38. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21(9):1715-1721.
39. Wilkinson S, Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 2004; 172(1):133-136.
40. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30(4):232-242.
41. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22(13): 2522-2531.
42. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57(17):3629-3634.
43. Vallabhajosula S, Kuji I, Hamacher KA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005; 46(4): 634-641.
44. Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005; 46(5):850-858.
45. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res 2005; 11(19 pt 2):7195s-200s.
46. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23(21):4591-1601.
47. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170(5): 1717-1721.
48. Sodee DB, Sodee AE, Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007; 37(1):17-28.
49. Seo Y, Franc BL, Hawkins RA, et al. Progress in SPECT/ CT imaging of prostate cancer. Technol Cancer Res Treat 2006; 5(4):329-336.
50. Noz ME, Chung G, Lee BY, et al. Enhancing the utility of prostascint SPECT scans for patient management. J Med Syst 2006; 30(2):123-132.
51. Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neo-vasculature. Clin Cancer Res 1999; 5(10):2674-2681.
52. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007; 25(5):540-547.
53. Takashima H, Egawa M, Imao T, et al. Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 2004; 171(6 pt 1):2268-2271.
54. Silva N Jr., Anselmi CE, Anselmi OE, et al. Use of the gamma probe in sentinel lymph node biopsy in patients with prostate cancer. Nucl Med Commun 2005; 26(12): 1081-1086.
55. Wawroschek F, Vogt H, Wengenmair H, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003; 70(4): 303-310.
56. Pagliarulo V, Hawes D, Brands FH, et al. Detection of occult lymph node metastases in locally advanced nodenegative prostate cancer. J Clin Oncol 2006; 24(18): 2735-2742.
57. Joslyn SA, Konety BR. Impact of extent of lymphadenec-tomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68(1):121-125.
58. Weckermann D, Goppelt M, Dorn R, et al. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006; 97(6):1173-1178.
59. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997; 38(6):842-847.
60. Roivainen A, Forsback S, Gronroos T, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000; 27(1):25-32.
61. Groves AM, Win T, Haim SB, et al. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007; 8(9):822-830.
62. Pieterman RM, Que TH, Elsinga PH, et al. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 2002; 43(2):167-172.
63. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4(4):267-273.
64. Sutinen E, Nurmi M, Roivainen A, et al. Kinetics of [(11) C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004; 31(3):317-324.
65. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocho-line PET. J Nucl Med 2006; 47(2):262-269.
66. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007; 244(3): 797-806.
67. de Jong IJ, Pruim J, Elsinga PH, et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44(1):32-38; discussion 8-9.
68. Scher B, Seitz M, Albinger W, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34(1):45-53.
69. de Jong IJ, Pruim J, Elsinga PH, et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003; 44(3):331-335.
70. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27(9):1415-1419.
71. Rinnab L, Blumstein NM, Mottaghy FM, et al. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007; 99(6):1421-1426.
72. Eschmann SM, Pfannenberg AC, Rieger A, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for Staging of prostate cancer. Nuklearmedizin 2007; 46(5): 161-168; quiz N47-N48.
73. Picchio M, Messa C, Landoni C, et al. Value of [11C] choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169(4): 1337-1340.
74. Cimitan M, Bortolus R, Morassut S, et al. [(18)F]fluo-rocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33(12): 1387-1398.
75. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35(1):18-23.
76. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008; 35(1):9-17.
77. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100(4):786-793.
78. Igerc I, Kohlfurst S, Gallowitsch HJ, et al. The value of (18)F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35(5):976-983.
79. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retro-pubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52(2): 423-429.
80. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42(12):1805-1814.
81. Wyss MT, Weber B, Honer M, et al. 18F-choline in experimental soft tissue infection assessed with auto-radiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31(3):312-316.
82. Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42(1):25-30.
83. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35(2): 253-263.
84. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001; 28(2):117-122.
85. Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30(4):607-611.
86. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44(4):549-555.
87. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43(2): 181-186.
88. Sandblom G, Sorensen J, Lundin N, et al. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006; 67(5): 996-1000.
89. Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006; 24(16):2513-2519.
90. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med 2003; 44(4): 556-558.
91. Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med 2007; 48(3):420-428.
92. Matthies A, Ezziddin S, Ulrich EM, et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004; 31(5):797.
93. Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol 2004; 31(7):859-865.
94. Zophel K, Kotzerke J. Is 11C-choline the most appropriate tracer for prostate cancer? Against. Eur J Nucl Med Mol Imaging 2004; 31(5):756-759.
95. Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/ or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007; 99(6):1415-1420.
96. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer. J Nucl Med 2008; 49(1):68-78.
97. Even-Sapir E, Mishani E, Flusser G, et al. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007; 37(6):462-469.
98. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42(12):1800-1804.
99. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47(2):287-297.
100. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36(1):73-92.
101. Miyazawa H, Arai T, Iio M, et al. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 1993; 34(11): 1886-1891.
102. Kubota K, Yamada K, Fukada H, et al. Tumor detection with carbon-11-labelled amino acids. Eur J Nucl Med 1984; 9(3):136-140.
103. Toth G, Lengyel Z, Balkay L, et al. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005; 173(1):66-69; discussion 9.
104. Dehdashti F, Picus J, Michalski JM, et al. Positron tomo-graphic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32(3): 344-350.
105. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45(3):366-373.
106. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42(3):432-145.
107. Oka S, Hattori R, Kurosaki F, et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007; 48(1):46-55.
108. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48(1):56-63.
109. Mangner TJ, Klecker RW, Anderson L, et al. Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-d-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. Nucl Med Biol 2003; 30(3): 215-224.
110. Sun H, Sloan A, Mangner TJ, et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005; 32(1):15-22.
111. Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004; 45(3): 519-525.
112. Katz S, Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 2006; 44(5):723-734, viii.
113. Kurhanewicz J, Vigneron D, Carroll P, et al. Multipara-metric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008; 18(1):71-77.
114. Huzjan R, Sala E, Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol 2005; 2(9):434-442.
115. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol 2007; 63(3):351-360.
116. Shen T, Weissleder R, Papisov M, et al. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 1993; 29(5):599-604.
117. Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography: study of a high-efficiency lymphotrophic agent. Radiology 1994; 191(1):225-230.
118. Pittet MJ, Swirski FK, Reynolds F, et al. Labeling of immune cells for in vivo imaging using magnetofluores-cent nanoparticles. Nat Protoc 2006; 1(1):73-79.
119. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348(25):2491-2499.
120. Harisinghani MG, Barentsz JO, Hahn PF, et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol 2002; 9(suppl 2):S312-313.
121. Heesakkers RA, Futterer JJ, Hovels AM, et al. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience. Radiology 2006; 239(2):481-487.
122. Saksena M, Harisinghani M, Hahn P, et al. Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. AJR Am J Roentgenol 2006; 187(6):W582-588.
123. Enochs WS, Harsh G, Hochberg F, et al. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999; 9(2):228-232.
124. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23(11):1407-1413.
125. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56(18):4096-1102.
126. Brakenhielm E, Burton JB, Johnson M, et al. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 2007; 121(10):2153-2161.
127. Meyer KL, Schwendner SW, Counsell RE. Potential tumor or organ-imaging agents. 30. Radioiodinated phos-pholipid ethers. J Med Chem 1989; 32(9):2142-2147.
128. Counsell RE, Schwendner SW, Meyer KL, et al. Tumor visualization with a radioiodinated phospholipid ether. J Nucl Med 1990; 31(3):332-336.
129. Pinchuk AN, Rampy MA, Longino MA, et al. Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues. J Med Chem 2006; 49(7):2155-2165.
130. Chen AP, Albers MJ, Cunningham CH, et al. Hyper-polarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med 2007; 58(6):1099-1106.
131. Zhang K, Aruva MR, Shanthly N, et al. PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer. J Nucl Med 2008; 49(1):112-121.
132. de Visser M, Bernard HF, Erion JL, et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 2007; 34(8):1228-1238.
133. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006; 47(3):492-501.
134. Lin KS, Luu A, Baidoo KE, et al. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjug Chem 2005; 16(1):43-50.
135. Prasanphanich AF, Nanda PK, Rold TL, et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007; 104(30):12462-2467.
136. Line BR, Mitra A, Nan A, et al. Targeting tumor angio-genesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005; 46(9):1552-1560.
137. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46(suppl 1): 172S-178S.
138. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003; 100(22):12590-2595.
139. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004; 61(1):1-11.
140. Su SL, Huang IP, Fair WR, et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995; 55(7):1441-1443.
141. Tasch J, Gong M, Sadelain M, et al. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 2001; 21(1-3):249-261.
142. Lange PH. ProstaScint scan for staging prostate cancer. Urology 2001; 57(3):402-406.
143. Haseman MK, Rosenthal SA, Polascik TJ. Capromab pendetide imaging of prostate cancer. Cancer Biother Radiopharm 2000; 15(2):131-140.
144. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 2001; 7(1):27-37.
145. Jackson PF, Cole DC, Slusher BS, et al. Design, synthesis, and biological activity of a potent inhibitor of the neuro-peptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 1996; 39(2):619-622.
146. Majer P, Jackson PF, Delahanty G, et al. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 2003; 46(10):1989-1996.
147. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 2001; 44(3):298-301.
148. Zhou J, Neale JH, Pomper MG, et al. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005; 4:1015-1026.
149. Humblet V, Lapidus R, Williams LR, et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005; 4(4):448-162.
150. Barinka C, Rovenska M, Mlcochova P, et al. structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 2007; 50(14): 3267-3273.
151. Barinka C, Starkova J, Konvalinka J, et al. A highresolution structure of ligand-free human glutamate carboxy-peptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007; 63(pt 3):150-153.
152. Mlcochova P, Plechanovova A, Barinka C, et al. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. FEBS J 2007; 274(18):4731-1741.
153. Pomper MG, Musachio JL, Zhang J, et al. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002; 1:96-101.
154. Foss CA, Mease RC, Fan H, et al. Radiolabeled Small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005; 11:4022-4028.
155. Mease RC, Dusich CA, Foss CA, et al. Synthesis of N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC, its biodistribution and use in imaging prostate cancer xenografts. Clin Cancer Res 2008; 14(10):3036-3043.
156. Banerjee SR, Foss CA, Mease RC, et al. Synthesis and evaluation of 99mTc/Re labeled PSMA inhibitors. J Nucl Med 2007; 48(suppl 2):18P.
157. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neo-vasculature. Cancer Res 1999; 59(13):3192-3198.
158. Guilarte T, Hammoud DA, McGlothan JL, et al. Dys-regulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res 2008; 99(1-3):324-332.
159. Gottweis H. Gene therapy and the public: a matter of trust. Gene Ther 2002; 9(11):667-669.
160. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest 2003; 111(11):1620-1629.
161. Gambhir SS, Herschman HR, Cherry SR, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2(1-2):118-138.
162. Singh A, Massoud TF, Deroose C, et al. Molecular imaging of reporter gene expression in prostate cancer: an overview. Semin Nucl Med 2008; 38(1):9-19.
163. Siddiqui F, Barton KN, Stricker HJ, et al. Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. Hum Gene Ther 2007; 18(4):312-322.
164. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007; 15(9):1600-1606.
165. Freytag SO, Movsas B, Aref I, et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007; 15(5):1016-1023.
166. Zanzonico PB, Finn R, Pentlow KS, et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004; 45(11):1966-1971.